Two antibody drugs that work by neutralising the SARS-CoV-2 virus' spike protein (foreground) are no longer recommended for treating Covid-19 due to their lack of effectiveness against current viral variants, including Omicron. — AFP/US NIH
The antibody drugs sotrovimab and casirivimab-imdevimab are not recommended for patients with Covid-19, said a World Health Organization (WHO) Guideline Development Group of international experts in The BMJ medical journal on Sept 16 (2022).
These drugs work by binding to the SARS-CoV-2 spike protein, neutralising the virus’s ability to infect cells.
Already a subscriber? Log in.
Subscribe now and receive FREE sooka plan for 1 month.
T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
